Jing Ji Guan Cha Wang·2026-01-06 08:58Core Viewpoint - Yunnan Kun Pharmaceutical Group has undergone significant management changes, with a new chairman and president appointed as the company aims to deepen its integration with China Resources Sanjiu and focus on the "healthy aging" sector [1][2]. Management Changes - The company announced the resignation of Chairman Wu Wendo, President Yan Wei, and Vice President Li Lichun, with Yu Xiang appointed as the new chairman and Zhong Jiang as the new president [1][2]. - Yu Xiang, aged 45, has extensive experience in various leadership roles within China Resources Sanjiu, while Zhong Jiang, aged 50, has held significant positions in financial management within the company [2]. Business Performance - Kun Pharmaceutical Group's overall performance has shown a downward trend, with a revenue decline in 2024 and a net profit increase. In 2025, the first three quarters also saw revenue and net profit declines, with a significant loss in the third quarter [3]. - In 2024, the company reported a revenue of 8.4 billion yuan, a decrease of 0.34% year-on-year, while net profit reached 648 million yuan, an increase of 19.86% [3]. - For the first three quarters of 2025, revenue was 4.751 billion yuan, down 18.08%, and net profit was 269 million yuan, down 39.42% [3]. Strategic Focus - The company aims to leverage its 70 years of drug research tradition and global marketing network to become a leader in the "silver health industry" and chronic disease management [1][4]. - Future development will focus on three core areas: cardiovascular products centered around Xuesaitong, emotional health products based on Shugan Granules, and products for mental health and pain management [4].